GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dawnrays Pharmaceutical (Holdings) Ltd (HKSE:02348) » Definitions » Tax Expense

Dawnrays Pharmaceutical (Holdings) (HKSE:02348) Tax Expense : HK$90 Mil (TTM As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Dawnrays Pharmaceutical (Holdings) Tax Expense?

Dawnrays Pharmaceutical (Holdings)'s tax expense for the months ended in Jun. 2024 was HK$70 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was HK$90 Mil.


Dawnrays Pharmaceutical (Holdings) Tax Expense Historical Data

The historical data trend for Dawnrays Pharmaceutical (Holdings)'s Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dawnrays Pharmaceutical (Holdings) Tax Expense Chart

Dawnrays Pharmaceutical (Holdings) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.36 78.84 104.28 92.19 99.96

Dawnrays Pharmaceutical (Holdings) Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.02 32.15 79.89 20.07 70.16

Dawnrays Pharmaceutical (Holdings) Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dawnrays Pharmaceutical (Holdings)  (HKSE:02348) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Dawnrays Pharmaceutical (Holdings) Tax Expense Related Terms

Thank you for viewing the detailed overview of Dawnrays Pharmaceutical (Holdings)'s Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Dawnrays Pharmaceutical (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
338 Hennessy Road, Units 3001-02, 30th Floor, CNT Tower, Wanchai, North Sea Centre, Hong Kong, HKG
Dawnrays Pharmaceutical (Holdings) Ltd is a drug manufacturing company. The company operates two segments, including Intermediates and Bulk Medicines, and Finished Drugs. The revenue is derived from the Finished Drugs segment. Nearly all of the company's sales are generated in Mainland China. It utilizes strategic partnerships as a component of its international strategies. The company is open to exploring potential acquisitions as a component of its overall growth plan.
Executives
Fortune United Group Limited 2101 Beneficial owner
Hunwick International Limited 2201 Interest of corporation controlled by you
Keysmart Enterprises Limited 2201 Interest of corporation controlled by you
Iu Pun 2202 Interest of your spouse
Li Tung Ming
Li Kei Ling
Hung Yung Lai
Fmr Llc 2201 Interest of corporation controlled by you
Toyo International Investment Limited
Leung Hong Man
Leung Yiu Sing
Chu Shuet Fong
Lo Mei Sai
Time Lead Investments Limited

Dawnrays Pharmaceutical (Holdings) Headlines

No Headlines